Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.
Epistemonikos ID: 50208bf16e71dc222c86a5fdab5a07f115055e5d
First added on: Oct 23, 2026